FOR JOURNALISTS AND MEDIA REPRESENTATIVES ONLY
Welcome to the Astellas media centre for the 59th European Renal Association (ERA) Congress, between 19 – 22 May 2022. Here you will find information on anaemia of chronic kidney disease (CKD), HIF-PH inhibition, perspectives from patients and the Astellas data being presented at this year’s ERA congress.
We hope that the information and resources available here are useful and informative. We thank you for taking the time to visit to learn more about Astellas’ activities at the congress.
Click on the below to explore further about:
- Astellas data presentations at ERA
- Media materials
- Media spokespersons
- A patient perspective
- Anaemia of CKD
Astellas data presentations at ERA
We feel privileged to attend and present at key nephrology congresses, such as ERA, to raise awareness of the unmet medical need in anaemia of CKD and the need for innovation in this area.
Astellas Analyses Shows No Evidence of Increased Risk of Cardiovascular Events or Mortality with Roxadustat Compared with Erythropoiesis-Stimulating Agents (ESAs) at 59th ERA Congress 2022
Click here to view the full press release.
Available from May 19, 2022, as a mini oral presentation
Title: Safety of Roxadustat Versus Erythropoiesis-Stimulating Agents for Treatment of Anaemia in Patients With Chronic Kidney Disease Incident to or Not Receiving Dialysis - view here
- Authors: Jonathan Barratt, MD, PhD, Frank Dellanna, MD, PhD, Jose Portoles, MD, PhD, Gabriel Choukroun, MD, PhD, Luca De Nicola, MD, PhD, Michael Reusch, MD, James Young, MS, Nada Dimković, MD, PhD
To understand the data presented, we have the following assets and spokespersons available to speak with the media. If you would like to schedule an interview, please contact: [email protected] or [email protected]
Professor Jonathan Barratt,
University of Leicester, United Kingdom
Professor Jonathan Barratt leads the Renal Research Group within the College of Life Sciences, University of Leicester. His research interests span a range of areas across renal medicine and include glomerular disease, multi-system renal disease and complications of chronic kidney disease, in particular renal associated anaemia. He is the IgA nephropathy Rare Disease Group lead for the UK National Registry of Rare Kidney Diseases (RaDaR) and a member of the steering committee for the International IgA Nephropathy Network. Jonathan is Chief Investigator for a number of international randomised controlled clinical trials, having attended both the FDA and EMA as an advisor for new therapies in IgA nephropathy, and is a member of the FDA and American Society of Nephrology Kidney Health Initiative: Identifying Surrogate Endpoints for Clinical Trials in IgA Nephropathy Workgroup. Jonathan is also an Editorial Board member for Kidney International and Clinical Journal of the American Society of Nephrology and sits on the Kidney Research UK Grants Committee.
Senior Vice President, Head of Development Therapeutic Areas, Astellas
Ahsan leads the Oncology and Medical Specialties Therapeutic Areas at Astellas, including the GDPLs and GMLs. Prior to joining the oncology development team in 2017, Ahsan made extensive contributions to the Astellas pharmacovigilance organization as the Oncology TA Head in PV Medical Safety. Prior to joining Astellas in 2008, Ahsan was an associate professor in the Department of Medicine, Sections of General Internal Medicine and Health Promotion Research at the University of Illinois at Chicago. Ahsan holds both a BS and an MD from Northwestern and an MPH from Harvard University School of Public Health.
Anaemia of CKD
To learn more about anaemia of CKD and Astella’s dedication to nephrology, visit our website at: https://www.astellas.com/eu/therapy-areas/nephrology
NEPH_2022_0031_UK. May 2022